Antiviral Treatment of Coronavirus Disease-2019 Pneumonia

Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available t...

Descripción completa

Detalles Bibliográficos
Autores principales: Radcliffe, Christopher, Malinis, Maricar, Azar, Marwan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701636/
https://www.ncbi.nlm.nih.gov/pubmed/37085220
http://dx.doi.org/10.1016/j.ccm.2022.11.008
_version_ 1784839577778782208
author Radcliffe, Christopher
Malinis, Maricar
Azar, Marwan M.
author_facet Radcliffe, Christopher
Malinis, Maricar
Azar, Marwan M.
author_sort Radcliffe, Christopher
collection PubMed
description Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.
format Online
Article
Text
id pubmed-9701636
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97016362022-11-28 Antiviral Treatment of Coronavirus Disease-2019 Pneumonia Radcliffe, Christopher Malinis, Maricar Azar, Marwan M. Clin Chest Med Article Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic. Elsevier Inc. 2023-06 2022-11-28 /pmc/articles/PMC9701636/ /pubmed/37085220 http://dx.doi.org/10.1016/j.ccm.2022.11.008 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Radcliffe, Christopher
Malinis, Maricar
Azar, Marwan M.
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title_full Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title_fullStr Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title_full_unstemmed Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title_short Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
title_sort antiviral treatment of coronavirus disease-2019 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701636/
https://www.ncbi.nlm.nih.gov/pubmed/37085220
http://dx.doi.org/10.1016/j.ccm.2022.11.008
work_keys_str_mv AT radcliffechristopher antiviraltreatmentofcoronavirusdisease2019pneumonia
AT malinismaricar antiviraltreatmentofcoronavirusdisease2019pneumonia
AT azarmarwanm antiviraltreatmentofcoronavirusdisease2019pneumonia

Ejemplares similares